Gallus BioPharmaceuticals

Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. Xcellerex FlexFactory® is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact clean room architecture. FlexFactory allows deployment of GMP manufacturing capacity more rapidly and at greatly reduced costs compared with traditional facilities. Xcellerex deployed its TransPlant™ process to install, validate, and train Gallus personnel in their own FlexFactory. This parallel-path model accelerated time to clinical and commercial manufacturing, allowing Gallus to manage the development of their customer's product while adding manufacturing capacity. Xcellerex has also leveraged its proprietary single-use technologies through the sale of additional XDR bioreactors, XDM Quad Mixers, and related single-use assemblies to Gallus site as well. To date, more than 20 therapeutic proteins and vaccines have been manufactured for clinical trials using Xcellerex technology. Xcellerex welcomes customers to experience the Xcellerex technology at a top tier clinical and commercial CMO, like Gallus.

Theorem Clinical Research
Corporate Headquarters

1016 West Ninth Avenue
King of Prussia, PA 19406

Toll-free: 1.800.290.5766

Email: information@theoremclinical.com
Web: http://www.theoremclinical.com/

Click Here for More Information

Theorem Clinical Research is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's leading pharmaceutical, biotech and medical device companies. A world leader in the most complex medical device and drug-device combination trials in addition to a notable capability in pharmaceuticals and biologics, Theorem has deep expertise in a broad range of therapeutic areas and in all phases of development. Some of the industry's top scientists and most advanced clinical analytics capabilities help ensure smooth-running, successful trials. For a full-service, right-size global research partner, don't think twice. THINK THEOREM.

NATRIX Separations, Inc.

5295 John Lucas Drive, Unit 6
Burlington, Ontario, L7L 6A8 Canada

Phone: 905-319-2682
Fax: 905-319-0430
Toll Free: 866-990-6972

Email: mcglaughlin@natrixseparations.com
Web: http://www.natrixseparations.com

Click Here for More Information

Natrix Separations is a leading supplier of high performance, single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Natrix Separations’ patented Advective™ chromatography technology combines the high binding capacity, selectivity and specificity associated with conventional resin-based chromatography with the high throughput and ease-of-use of traditional membrane products. The product consists of a polymeric hydrogel formed within a flexible porous support matrix. The support matrix provides mechanical strength, while the hydrogel properties determine the separation chemistry of the product. The Natrix Chromatography technology now enables single use for primary capture through final polish. For additional information, visit http://www.natrixseparations.com, or contact Molly S. McGlaughlin VP, Business Development, mcglaughlin@natrixseparations.com, or call 617-548-7927, or toll-free at 866-990-6972.

Roslin Cells

Edinburgh bioQuarter
5 Little France Drive
Edinburgh, EH16 4UU

Phone: +44 (0) 131 651 9610
Fax: +44 (0)131 651 9611

Email: info@roslincells.com
Web: http://www.roslincells.com

Roslin Cells Ltd is headquartered in Edinburgh, Scotland. It was established as an independent non-profit company by Roslin Institute in 2006 to assist academic and commercial research organizations to transform fundamental research into new cell therapies. It is currently licensed by The Human Fertilisation and Embryology Authority and the Human Tissue Authority and is currently preparing to receive a GMP Manufacturer's license inspection from the Medicines and Healthcare Products Regulatory Agency (MHRA). With the assistance of its primary stakeholders, the Roslin Foundation, the University of Edinburgh, the Scottish National Blood Transfusion Service and Scottish Enterprise Roslin Cells is able to provide a strong partner for the development of cellular therapies. For more information please see www.roslincells.com, email info@roslincells.com, or telephone +44 (0) 131 651 9610.